[
    [
        {
            "time": "",
            "original_text": "白云山(00874)：广药集团被纳入国企改革‘双百企业’名单",
            "features": {
                "keywords": [
                    "白云山",
                    "广药集团",
                    "国企改革",
                    "双百企业"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药",
                    "国企改革"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "白云山(00874)：广药集团被纳入国企改革‘双百企业’名单",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "白云山(00874.HK)：广药集团获新增纳入国企改革‘双百企业’名单",
            "features": {
                "keywords": [
                    "白云山",
                    "广药集团",
                    "国企改革",
                    "双百企业"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药",
                    "国企改革"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "白云山(00874.HK)：广药集团获新增纳入国企改革‘双百企业’名单",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "白云山：控股股东被纳入‘双百企业’名单",
            "features": {
                "keywords": [
                    "白云山",
                    "控股股东",
                    "双百企业"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药",
                    "国企改革"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "白云山：控股股东被纳入‘双百企业’名单",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "ED市场群雄逐鹿，‘伟哥之王’2019年或将易主？",
            "features": {
                "keywords": [
                    "ED市场",
                    "伟哥",
                    "2019年",
                    "易主"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "制药",
                    "市场竞争"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "ED市场群雄逐鹿，‘伟哥之王’2019年或将易主？",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "白云山（600332.SH）2019年一季报点评：春季发货助力利润高增长，维持‘买入’评级",
            "features": {
                "keywords": [
                    "白云山",
                    "2019年一季报",
                    "利润高增长",
                    "买入评级"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "制药",
                    "财务表现"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "白云山（600332.SH）2019年一季报点评：春季发货助力利润高增长，维持‘买入’评级",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]